Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 10/20 | 0.72 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.57 |
| ▸ | CDK2 | P24941 | 9/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388457 | 0.95 | CDK5 (0.83) | CDK5CDK5R1CCNA2CDK2ADORA2A | |
| SCHEMBL3386683 | 0.91 | CDK5 (0.74) | CDK5CDK5R1CCNA2CDK2ADORA2A | |
| SCHEMBL14073849 | 0.88 | CDK5 (0.67) | CDK5CDK5R1CCNA2CDK2KDM4E | |
| SCHEMBL3384712 | 0.87 | CCNA2 (0.74) | CDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL3384847 | 0.87 | CDK5 (0.70) | CDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL14073860 | 0.86 | CDK5 (0.67) | CDK5CDK5R1CCNA2CDK2 | |
| SCHEMBL28765718 | 0.86 | CDK5 (0.69) | CDK5CDK5R1CCNA2CDK2KDM4E | |
| SCHEMBL27686737 | 0.85 | CDK5 (0.68) | CDK5CDK5R1CCNA2CDK2KDM4E | |
| SCHEMBL14073903 | 0.85 | CDK5 (0.52) | CDK5CDK5R1CCNA2CDK2ADORA2A | |
| SCHEMBL28765719 | 0.84 | CDK5 (0.67) | CDK5CDK5R1CCNA2CDK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771424-B1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-15 | — | — | EP | claimed |
| US-7423053-B2 | 4-Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | claimed |
| EP-1771424-A1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | claimed |
| WO-2006005508-A1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | claimed |
| US-20060014958-A1 | 4-Aminothiazole derivatives | CHEN LI | 2006-01-19 | — | — | US | claimed |
| EP-1771424-B1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-15 | — | — | EP | disclosed |
| EP-1771424-B1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-7423053-B2 | 4-Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423053-B2 | 4-Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423053-B2 | 4-Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1771424-A1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| US-20060014958-A1 | 4-Aminothiazole derivatives | CHEN LI | 2006-01-19 | — | — | US | disclosed |
| WO-2006005508-A1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014958-A1 | 4-Aminothiazole derivatives | CDK4, CDK2, CCNI | CDK5 19/4885CDK5R1 49/4885CCNA2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.